ASND Ascendis Pharma
Price Chart
Executive Summary
Ascendis Pharma reported positive subgroup data from the ApproaCH trial of TransCon CNP (navepegritide) in achondroplasia. Children ≥5 years showed significantly greater annualized growth velocity vs placebo at Week 52 (+1.78 cm/year, p<0.0001) with sustained improvements through Week 104. The drug was already FDA-approved in February 2026; the data strengthens the profile and supports ongoing EU regulatory review.
Actionable Insight
The data is confirmatory and unlikely to materially move the stock given prior FDA approval. Monitor EU regulatory decision in Q4 2026 and early sales trends of YUVIWEL. No immediate trading catalyst.
Key Facts
- Subgroup of children ≥5 years at enrollment: AGV treatment difference +1.78 cm/year vs placebo at Week 52 (p<0.0001)
- Sustained growth improvements observed through Week 104
- Safety profile consistent with overall population; no symptomatic hypotension or bone age acceleration
- TransCon CNP (YUVIWEL) FDA-approved February 2026 for achondroplasia in patients ≥2 years
- EU regulatory decision expected Q4 2026
Financial Impact
No direct financial impact from this data; may support commercial uptake and EU approval
Risk Factors
- Potential delays or negative outcome in EU regulatory review
- Competition from other achondroplasia therapies (e.g., vosoritide)
- Reimbursement and market access challenges
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289301 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 13, 2026
1d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
Jun 12, 2026
2d ago
|
6-K
| $215.32 awaiting T+1 | awaiting T+1 | — | $218.06 (+1.27%) |
|
Jun 2, 2026
12d ago
|
Insider Cluster
| $216.79 $218.84 | ▲ +0.95% | ▲ +0.55% | $218.06 (+0.59%) |
|
May 19, 2026
26d ago
|
ANALYST-UPGRADE
| $237.98 $241.34 | ▲ +1.41% | ▲ +0.37% | $218.06 (−8.37%) |
|
May 16, 2026
29d ago
|
ANALYST-UPGRADE
| $170.74 $162.84 | ▼ −4.63% | ▼ −3.78% | $218.06 (+27.71%) |
|
May 7, 2026
5w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $218.06 (−11.41%) |
|
May 7, 2026
5w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $218.06 (−11.41%) |
|
May 6, 2026
5w ago
|
Press Release
| $246.14 $246.14 | · 0.00% | ▼ −0.83% | $218.06 (−11.41%) |
|
Apr 21, 2026
7w ago
|
6-K
| $240.29 $231.05 | ▼ −3.85% | ▼ −4.86% | $218.06 (−9.25%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $242.95 $244.48 | ▲ +0.63% | ▼ −0.58% | $218.06 (−10.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access